First-Line Eftilagimod Alpha Plus Pembrolizumab Generates OS Benefits in PD-L1+ NSCLC
Eftilagimod alfa (efti; IMP321) plus pembrolizumab (Keytruda) provided overall survival (OS) benefit compared with historical controls when given as first-line treatment in patients with non-small cell lung cancer (NSCLC) and …
First-Line Eftilagimod Alpha Plus Pembrolizumab Generates OS Benefits in PD-L1+ NSCLC Read More